The Effects of L-Arabinose and D-xylose on Intestinal Sucrase Activity in Man

Insulin Resistance Clinical Trial

— M192  

Official title:

The Effects of L-Arabinose and D-xylose on Intestinal Sucrase Activity in Man

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01957098
• Other study ID #: (KF) 11 324909
• Status: Completed
• Phase: N/A
• First received: August 8, 2013
• Last updated: October 7, 2013
• Start date: October 2006
• Est. completion date: May 2007

Study information

• Verified date: October 2013
• Source: University of Copenhagen
• Contact: n/a
• Is FDA regulated: No
• Health authority: Denmark: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the effect of L-arabinose and D-xylose in a sugar-rich drink on intestinal sucrase activity in healthy volunteers by measuring postprandial blood glucose and insulin, and selected intestinal hormonal responses to increasing doses of L-arabinose and D-xylose.

Description:

Based on previous scientific results we hypotesize, that pentoses decreases the demand for insulin in metabolizing a given dose of sucrose.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 14
• Est. completion date: May 2007
• Est. primary completion date: January 2007
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 30 Years

Eligibility

Inclusion Criteria:

• healthy males

• BMI between 18.4-25 kg/m2

• age between 18 and 30

Exclusion Criteria:

• donation of blood 3 months before or during the study

• gastrointestinal disorders, diabetes, hypertension, hyperlipidemia, chronic infectious disease (HIV or hepatitis)

• smoking

• consumption of more than 21 alcoholic drinks/week

• elite athletes

• on medication

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Insulin Resistance

Intervention

Dietary Supplement:
• Placebo comparator: 0% pentose
14 healthy subjects participated in a randomized double-blinded cross-over study based on four single tests. Sucrose containing drinks were supplemented with two different doses of D-xylose and in addition one dose of L-arabinose was included for comparison with earlier studies. Blood was collected fasting and for 3-h postprandially. Appetite sensations and energy intake were registered. Gastrointestinal symptoms were monitored for 24 hours
• Active comparator: 4% D-xylose

• Active comparator: 8% D-xylose

• Active comparator: 8% L-arabinose

Locations

Country	Name	City	State
Denmark	Institute of Human Nutrition, The Royal Veterinary and Agricultural University	Frederiksberg

Sponsors (2)

Lead Sponsor	Collaborator
University of Copenhagen	Danisco

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood glucose, insulin, C-peptide and GLP-1	Level of glucose, insulin, C-peptide and glucagon-like peptide-1 (GLP-1) over time, the area under the curve (AUC), the peak value and time to peak	-15, 0, 15, 30, 45, 60, 90, 120, 180 min	No
Secondary	Appetite measurements and energy intake	Appetite measurements: area under/over the curve (AUC/AOC), 3-h mean. Energy intake: the ad libitum energy intake at lunch was registered. VAS was used to asses the palatability (appearance, smell, taste, after-taste and overall palatability) of the ad libitum lunch.	-15, 30, 60, 90, 120, 150 and 180 min	No